Repeatedly injecting in the same location can lead to lipohypertrophy, a condition characterized by lumpy, thickened areas of fatty tissue that can impair medication absorption and lead to unpredictable blood glucose levels
The blood work they do as part of the process showed me that they genuinely care about identifying any personal health risks before they become a problem
Nausea The most commonly reported side effect across all GLP-1 medications, including drops
Scenario A: Metabolic Rescue (High Risk, Suitable for Application) Target population: women with BMI 30 kg/m 2 plus marked IR or metabolic syndrome
In the Phase REDEFINE 4 trial, CagriSemaa fixed dose combo of 2.4 mg semaglutide and 2.4 mg cagrilintideelicited 23% weight loss over 84 weeks compared to Zepbounds 25.5%
Compared with metformin and second- or third-line glucose-lowering medication groups, major adverse CVEs were significantly lower in patients with NAFLD and type 2 diabetes taking GLP-1RAs, but not different from those taking SGLT2 inhibitors